Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2A | Q9UQM7 | 6/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1162806 | 0.85 | KCNQ4 (0.44) | NR1H4PTGDR2RXFP1BRD4 | |
| SCHEMBL1162987 | 0.81 | NR1H4 (0.58) | NR1H4RXFP1 | |
| SCHEMBL30619395 | 0.81 | NR1H4 (0.58) | NR1H4RXFP1 | |
| SCHEMBL24362149 | 0.81 | HPGD (0.47) | NQO2MIFRXFP1 | |
| SCHEMBL29618957 | 0.81 | HPGD (0.47) | NQO2MIFRXFP1 | |
| SCHEMBL11346674 | 0.80 | NQO2 (0.47) | CAMK2ANQO2EGFR | |
| SCHEMBL24253781 | 0.78 | NQO2 (0.45) | NQO2MIFRXFP1EGFR | |
| SCHEMBL31470226 | 0.78 | CYP3A4 (0.45) | NQO2MIFRXFP1 | |
| SCHEMBL13636106 | 0.78 | CYP3A4 (0.45) | NQO2MIFRXFP1 | |
| SCHEMBL28736190 | 0.78 | NR1H4 (0.45) | NQO2NR1H4PTGDR2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002068428-A1 | METHOD OF PREPARING CEPHALOSPORINS USING 4-HYDROXYPHENYLGLYCINE DERIVATIVES | HANMI PHARM. CO., LTD. (KR) | 2002-09-06 | — | — | WO | disclosed |
| US-20020120136-A1 | Method of preparing cephalosporins using 4-hydroxyphenylglycine derivatives | HANMI PHARM. CO., LTD. (KR) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120136-A1 | Method of preparing cephalosporins using 4-hydroxyphenylglycine derivatives | GYPA, PEPD, HPD | CAMK2A 4218/4885NQO2 1038/4885NR1H4 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.